Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC
May 20th 2020Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.
FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma
January 21st 2020The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
January 16th 2020The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
Endocrine Toxicities May Be a Unique AE Associated with Immunotherapy
August 23rd 2019Like most other adverse events (AEs), nurses play a vital role in monitoring for and managing endocrine toxicities associated with immunotherapy treatment; however, these may be more unique than others, according to Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP.
Patient Navigation Project Builds Foundation to Improve Breast Cancer Outcomes
June 27th 2019With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.
Ongoing TRANSCEND Trial May Offer Hope to MCL Subset
June 12th 2019The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving, though patients with relapsed/refractory disease tend to still have poorer outcomes than others; however, hope may be on the horizon, according to Luhua (Michael) Wang, MD.
PARP Inhibitor Improves PFS in Pancreatic Cancer Subset
June 3rd 2019Maintenance therapy with olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer, according to results from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.